EuroPharma Today

Invitation to Innovative Drug R&D in Russia Forum

Adam Smith Conferences’ Innovative Drug R&D in Russia Forum will take place on 21-22 November in Moscow.

This years’ Forum is set to become the one industry gathering that you cannot afford to miss!

Amsterdam Molecular Therapeutics Ends Glybera Development, Halves Workforce

Amsterdam Molecular Therapeutics BV's potential gene therapy, Glybera (alipogene tiparvovec), may have been rejected for approval by Europe's top scientific advisory panel, CHMP, on Oct. 21, but the closeness of the vote - there was only one dissenting voice - suggests it won't be long before a gene therapy product clears the committee and reaches the European market.

Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review

Merck KGaA's pharmaceuticals division, Merck Serono, has returned global rights to the late-stage Parkinson's disease therapy safinamide to the Italian biotech Newron Pharmaceuticals SPA. The surprise decision comes just a week before Newron's shareholders were due to vote on its proposed merger with Finland's Biotie Therapies Corp.

Lacking Mediator EC Tightens Pharmacovigilance Proposals

The biggest changes in the European Commission's revised proposals on how pharmaceutical manufacturers can provide information to patients don't have to do with communications to patients at all - they address reporting safety concerns to regulators.

Teva Launches Generic Salmeterol in the U.K. To Compete With GSK's Serevent

Teva Pharmaceuticals Industries Ltd. has succeeded in piercing the market exclusivity surrounding GlaxoSmithKline PLC's inhaled asthma products with a "first-to-market" launch on Oct.7 in the U.K. of a salmeterol xinafoate inhaler.

Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs

The Swedish government published on Sept. 22 a framework directive designed to revolutionize the pricing, reimbursement of and access to patent-protected pharmaceuticals.